Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2019
SIETES contiene 92824 citas

 
 
 1 a 20 de 20 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
3.Tiene citas relacionadas
Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. JAMA Intern Med 2015;175:408-9. [Ref.ID 98843]
4.Tiene citas relacionadas Cita con resumen
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Krane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. JAMA Intern Med 2015;175:401-7. [Ref.ID 98842]
5. Cita con resumen
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626. [Ref.ID 97343]
6. Cita con resumen
Anónimo. Prises de poids d'origine médicamenteuse. Prescrire 2011;31:748-52. [Ref.ID 91601]
7. Cita con resumen
Eiland LS, Jenkins LS, Durham SH. Pediatric migraine: pharmacologic agents for prophylaxis. Ann Pharmacother 2007;41:1181-90. [Ref.ID 80766]
8. Cita con resumen

Se ha producido un error durante la generación de la página

. Infant deaths associated with cough and cold medications --- Two states, 2005. MMWR Morb Mortal Wkly Rep 2007;56:1-4. [Ref.ID 80644]
9.
Velez LI, Shepherd G, Roth B A, Benitez FL. Serotonin syndrome with elevated paroxetine concentrations. Ann Pharmacother 2004;38:269-72. [Ref.ID 69277]
10. Cita con resumen
Anónimo. Oral antihistamines for allergic disorders. Drug Ther Bull 2002;40:59-62. [Ref.ID 64554]
11.Tiene citas relacionadas
McDaniel WW. Comment: serotonin syndrome, mydriasis, and cyproheptadine. Author's reply. Ann Pharmacother 2001;35:1673. [Ref.ID 60982]
12.Tiene citas relacionadas Cita con resumen
Isbister GK. Comment: serotonin syndrome, mydriasis, and cyproheptadine. Ann Pharmacother 2001;35:1672-3. [Ref.ID 60981]
13.
McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother 2001;35:870-3. [Ref.ID 58438]
14.
Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001;61:499-514. [Ref.ID 56030]
15.
Shaw S, Fletcher AP. Aggression as an adverse drug reaction. Adverse Drug React Toxicol Rev 2000;19:35-45. [Ref.ID 49927]
16.
McCarthy M, Wilkinson ML. Hepatology. BMJ 1999;318:1256-9. [Ref.ID 44959]
17.
Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55:675-88. [Ref.ID 38013]
18.
Hodes M. Feeding disorders. Prescr J 1995;35:192-8. [Ref.ID 25359]
19.
Anónimo. Drug control authority bans seven undesirable drugs. Lancet 1986;2:1210. [Ref.ID 9738]
20.
Anónimo. Cyproheptadine. Lancet 1978;1:367-8. [Ref.ID 3831]
Seleccionar todas
 
 1 a 20 de 20